GATINEAU, QC, Jan. 17, 2022 / – Public Services and Procurement Canada – Today, the Honourable Filomena Tassi, Minister of Public Services and Procurement, announced that the Government of Canada has received an initial shipment of 30,400 treatment courses of Pfizer’s COVID-19 oral antiviral treatment, PAXLOVIDTM, with 120,000 more expected to be delivered between now and the end of March. The treatment received Health Canada regulatory authorization earlier today.
PFIZER PAXLOVID ARRIVES IN CANADA TO COMBAT COVID-19
Vaccination and public health measures remain the best way to protect the public against infection and severe disease. However, access to effective, easy-to-use treatments, such as the one produced by Pfizer, could be critical to reducing the severity of COVID-19 in people who become infected.
Distribution to provinces and territories will begin imminently. The Government of Canada is working closely with the provinces and territories to coordinate distribution of treatment courses across the country. The Public Health Agency of Canada met with provincial and territorial officials to discuss deployment based on a per capita basis with adjustments due to shipping requirements from Pfizer.
CANADA SECURES 1 MILLION DOSES OF PAXLOVID
Canada has secured 1 million courses of the treatment. Delivery schedules are being finalized, with the intent of bringing additional treatment courses to Canada as quickly as possible.
- Public Services and Procurement Canada and the Public Health Agency of Canada are working together to purchase and distribute COVID-19 vaccines, treatments and related supplies.
- On January 17, 2021, Health Canada authorized the use of Pfizer’s oral antiviral treatment, PAXLOVIDTM, to treat mild to moderate COVID-19 in non-hospitalized adults who are at high risk of progressing to serious illness, including hospitalization or death.
- Canada also secured access to 500,000 courses of Merck’s COVID-19 oral antiviral treatment, molnupiravir, with options for up to 500,000 more, pending Health Canada’s authorization.